Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Diczfalusy U et al. | 4beta-hydroxycholesterol as an endogenous marker for CYP3A4/5 activity. Stability and half-life of elimination after induction with rifampicin. | 2009 | Br J Clin Pharmacol | pmid:19006545 |
Tomalik-Scharte D et al. | Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric? | 2009 | Clin. Pharmacol. Ther. | pmid:19458613 |
Allmyr M et al. | Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. | 2009 | Basic Clin. Pharmacol. Toxicol. | pmid:19686543 |
Lütjohann D et al. | 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. | 2009 | Int J Clin Pharmacol Ther | pmid:19954708 |
Yang Z and Rodrigues AD | Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? | 2010 | J Clin Pharmacol | pmid:20197489 |
Gebeyehu E et al. | Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. | 2011 | Pharmacogenomics J. | pmid:20231858 |
Diczfalusy U et al. | 4β-Hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. | 2011 | Br J Clin Pharmacol | pmid:21219398 |
Nylén H et al. | Cytochrome P450 3A activity in mothers and their neonates as determined by plasma 4β-hydroxycholesterol. | 2011 | Eur. J. Clin. Pharmacol. | pmid:21246351 |
van de Merbel NC et al. | A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. | 2011 | J Pharm Biomed Anal | pmid:21507593 |
Peters J et al. | Oral absorption of clarithromycin is nearly abolished by chronic comedication of rifampicin in foals. | 2011 | Drug Metab. Dispos. | pmid:21690264 |